Lewis Lung Cancer Cells Promote SIGNR1(CD209b)-Mediated Macrophages Polarization Induced by IL-4 to Facilitate Immune Evasion

Journal of Cellular Biochemistry

Volumn 117, Issue 5, 2016, Pages 1158-1166

  Yan, Xiaolong ^a   Li, Wenhai ^a   Pan, Lei ^a   Fu, Enqing ^a   Xie, Yonghong ^a   Chen, Min ^a   Mu, Deguang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

IL 4; IMMUNE EVASION; LUNG CANCER; MURINE MACROPHAGE POLARIZATION; SIGNR1

Indexed keywords

CD209 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; BLOCKING ANTIBODY; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; DC-SPECIFIC ICAM-3 GRABBING NONINTEGRIN; LECTIN;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CELL MIGRATION; CELL POLARITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FILTERS AND MEMBRANES; IMMUNE DEFICIENCY; IMMUNE EVASION; LEWIS CARCINOMA; LUNG CANCER; LUNG CANCER CELL LINE; MACROPHAGE; MIXED CELL CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STIMULATION; TH1 CELL; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; C57BL MOUSE; CELL CULTURE; CELL LINE; CELL MOTION; CELL PROLIFERATION; COCULTURE; CYTOLOGY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR ESCAPE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, BLOCKING; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL ADHESION MOLECULES; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LECTINS, C-TYPE; MACROPHAGE ACTIVATION; MACROPHAGES; MICE, INBRED C57BL; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84960191969     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25399     Document Type: Article

References (37)

1. Amin R, Mourcin F, Uhel F, Guirriec M, Lamy T, Tarte K,. 2014. DC-SIGN Binds preferentially highly glycosylated IgM to trigger classical BCR signaling in follicular lymphoma. Blood 124: 2968-2968.
2. Beider K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, Abraham M, Wald H, Galun E, Peled A, Nagler A,. 2014. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget 5: 11283-11296.
3. Besnard A-G, Guabiraba R, Niedbala W, Palomo J, Reverchon F, Shaw TN, Couper KN, Ryffel B, Liew FY,. 2015. IL-33-Mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. PLoS Pathog 11: e1004607.
4. Brandt EB, Sivaprasad U,. 2011. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2: 110.
5. Califano R, Karamouzis M, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J,. 2014. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee. Lung Cancer 85: 74-80.
6. Cheong C, Matos I, Choi JH, Schauer JD, Dandamudi DB, Shrestha E, Makeyeva JA, Li X, Li P, Steinman RM, Park CG,. 2010. New monoclonal anti-mouse DC-SIGN antibodies reactive with acetone-fixed cells. J Immunol Methods 360: 66-75.
7. Croci DO, Fluck MFZ, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG,. 2007. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 56: 1687-1700.
8. Emens LA,. 2010. Chemoimmunotherapy. Cancer J 16: 295-303.
9. Garcia-Vallejo JJ, van Kooyk Y,. 2013. The physiological role of DC-SIGN: A tale of mice and men. Trends Immunol 34: 482-486.
10. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M,. 2009. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 59: 300-305.
11. Kuiper JL, Heideman DA, Thunnissen E, Paul MA, van Wijk AW, Postmus PE, Smit EF,. 2014. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 85: 19-24.
12. Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, Lu J, Liu J,. 2013. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat 12: 259-267.
13. Lanoue A, Clatworthy MR, Smith P, Green S, Townsend MJ, Jolin HE, Smith KG, Fallon PG, McKenzie AN,. 2004. SIGN-R1 contributes to protection against lethal pneumococcal infection in mice. J Exp Med 200: 1383-1393.
14. Lefevre L, Lugo-Villarino G, Meunier E, Valentin A, Olagnier D, Authier H, Duval C, Dardenne C, Bernad J, Lemesre JL, Auwerx J, Neyrolles O, Pipy B, Coste A,. 2013. The C-type lectin receptors dectin-1, MR, and SIGNR3 contribute both positively and negatively to the macrophage response to Leishmania infantum. Immunity 38: 1038-1049.
15. Lewis CE, Pollard JW,. 2006. Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612.
16. Liu C-Y, Xu J-Y, Shi X-Y, Huang W, Ruan T-Y, Xie P, Ding J-L,. 2013. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 93: 844-854.
17. Long KB, Beatty GL,. 2013. Harnessing the antitumor potential of macrophages for cancer immunotherapy. Oncoimmunol 2:e 26860.
18. Lorusso G, Ruegg C,. 2008. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130: 1091-1103.
19. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A,. 2002. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
20. Mesman AW, de Vries RD, McQuaid S, Duprex WP, de Swart RL, Geijtenbeek TB,. 2012. A prominent role for DC-SIGN+ dendritic cells in initiation and dissemination of measles virus infection in non-human primates. PLoS ONE 7: e49573.
21. Nagaoka K, Takahara K, Tanaka K, Yoshida H, Steinman RM, Saitoh S, Akashi-Takamura S, Miyake K, Kang YS, Park CG, Inaba K,. 2005. Association of SIGNR1 with TLR4-MD-2 enhances signal transduction by recognition of LPS in gram-negative bacteria. Int Immunol 17: 827-836.
22. Nonaka M, Ma BY, Imaeda H, Kawabe K, Kawasaki N, Hodohara K, Kawasaki N, Andoh A, Fujiyama Y, Kawasaki T,. 2011. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J Biol Chem 286: 22403-22413.
23. Odegard JM, Kelley-Clarke B, Tareen SU, Campbell DJ, Flynn PA, Nicolai CJ, Slough MM, Vin CD, McGowan PJ, Nelson LT, Ter Meulen J, Dubensky TW, Jr., Robbins SH,. 2015. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy. J Immunother 38: 41-53.
24. Park SJ, Burdick MD, Mehrad B,. 2012. Neutrophils mediate maturation and efflux of lung dendritic cells in response to Aspergillus fumigatus germ tubes. Infect Immun 80: 1759-1765.
25. Pircher A, Gamerith G, Amann A, Reinold S, Popper H, Gächter A, Pall G, Wöll E, Jamnig H, Gastl G,. 2014. Neoadjuvant chemo-immunotherapy modifies CD4+ CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. Lung Cancer 85: 81-87.
26. Powlesland AS, Ward EM, Sadhu SK, Guo Y, Taylor ME, Drickamer K,. 2006. Widely divergent biochemical properties of the complete set of mouse DC-SIGN-related proteins. J Biol Chem 281: 20440-20449.
27. Prabagar MG, Do Y, Ryu S, Park JY, Choi HJ, Choi WS, Yun TJ, Moon J, Choi IS, Ko K, Ko K, Young Shin C, Cheong C, Kang YS,. 2013. SIGN-R1, a C-type lectin, enhances apoptotic cell clearance through the complement deposition pathway by interacting with C1q in the spleen. Cell Death Differ 20: 535-545.
28. Saunders SP, Barlow JL, Walsh CM, Bellsoi A, Smith P, McKenzie AN, Fallon PG,. 2010. C-type lectin SIGN-R1 has a role in experimental colitis and responsiveness to lipopolysaccharide. J Immunol 184: 2627-2637.
29. Srivastava V, Manchanda M, Gupta S, Singla R, Behera D, Das G, Natarajan K,. 2009. Toll-like receptor 2 and DC-SIGNR1 differentially regulate suppressors of cytokine signaling 1 in dendritic cells during Mycobacterium tuberculosis infection. J Biol Chem 284: 25532-25541.
30. Takahara K, Arita T, Tokieda S, Shibata N, Okawa Y, Tateno H, Hirabayashi J, Inaba K,. 2012. Difference in fine specificity to polysaccharides of Candida albicans mannoprotein between mouse SIGNR1 and human DC-SIGN. Infect Immun 80: 1699-1706.
31. Takahara K, Yashima Y, Omatsu Y, Yoshida H, Kimura Y, Kang YS, Steinman RM, Park CG, Inaba K,. 2004. Functional comparison of the mouse DC-SIGN, SIGNR1, SIGNR3 and Langerin, C-type lectins. Int Immunol 16: 819-829.
32. Takahara K, Yashima Y, Omatsu Y, Yoshida H, Kimura Y, Kang YS, Steinman RM, Park CG, Inaba K,. 2004. Functional comparison of the mouse DC-SIGN, SIGNR1, SIGNR3 and Langerin, C-type lectins. Int Immunol 16: 819-829.
33. Tanne A, Ma B, Boudou F, Tailleux L, Botella H, Badell E, Levillain F, Taylor ME, Drickamer K, Nigou J, Dobos KM, Puzo G, Vestweber D, Wild MK, Marcinko M, Sobieszczuk P, Stewart L, Lebus D, Gicquel B, Neyrolles O,. 2009. A murine DC-SIGN homologue contributes to early host defense against Mycobacterium tuberculosis. J Exp Med 206: 2205-2220.
34. van Kooyk Y, Geijtenbeek TB,. 2003. DC-SIGN: Escape mechanism for pathogens. Nat Rev Immunol 3: 697-709.
35. Weiskopf K, Weissman IL,. 2015. Macrophages are critical effectors of antibody therapies for cancer. MAbs 7: 303-310.
36. Yu H, Kortylewski M, Pardoll D,. 2007. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41-51.
37. Ziegler A, Heidenreich R, Braumüller H, Wolburg H, Weidemann S, Mocikat R, Röcken M,. 2009. EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 113: 3494-3502.